| editorial | Q871232 |
| scholarly article | Q13442814 |
| P50 | author | John Ioannidis | Q6251482 |
| Marco Solmi | Q56816482 | ||
| P2093 | author name string | A F Carvalho | |
| C U Correll | |||
| P2860 | cites work | Plea for routinely presenting prediction intervals in meta-analysis | Q38842585 |
| The Mass Production of Redundant, Misleading, and Conflicted Systematic Reviews and Meta-analyses | Q38952676 | ||
| Adverse events in randomized trials: neglected, restricted, distorted, and silenced. | Q45909501 | ||
| Enhancing reproducibility for computational methods | Q46114847 | ||
| AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both | Q47684085 | ||
| Data sharing and reanalysis of randomized controlled trials in leading biomedical journals with a full data sharing policy: survey of studies published in The BMJ and PLOS Medicine | Q50027688 | ||
| Dietary fiber and health outcomes: an umbrella review of systematic reviews and meta-analyses | Q51760592 | ||
| The Proposal to Lower P Value Thresholds to .005. | Q52642658 | ||
| Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis | Q52687120 | ||
| Prespecified falsification end points: can they validate true observational associations? | Q53112716 | ||
| New Effect Size Rules of Thumb | Q62111546 | ||
| Can quality of clinical trials and meta-analyses be quantified? | Q77326667 | ||
| Next-generation systematic reviews: prospective meta-analysis, individual-level data, networks and umbrella reviews | Q89337194 | ||
| Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials | Q22306552 | ||
| An exploratory test for an excess of significant findings | Q24273224 | ||
| Comparison of evidence on harms of medical interventions in randomized and nonrandomized studies | Q24282604 | ||
| Reproducible Research Practices and Transparency across the Biomedical Literature | Q24288789 | ||
| The ASA's statement on p-values: context, process, and purpose | Q24492532 | ||
| The case of the misleading funnel plot | Q24676535 | ||
| Bias in meta-analysis detected by a simple, graphical test | Q24685585 | ||
| Quantifying heterogeneity in a meta-analysis | Q27860672 | ||
| Environmental Risk Factors and Amyotrophic Lateral Sclerosis: An Umbrella Review and Critical Assessment of Current Evidence from Systematic Reviews and Meta-Analyses of Observational Studies | Q28066972 | ||
| Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis | Q28293647 | ||
| A manifesto for reproducible science | Q28341964 | ||
| Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials | Q29620299 | ||
| Reanalyses of randomized clinical trial data | Q30849007 | ||
| Placebo--efficacy and adverse effects in controlled clinical trials | Q33656778 | ||
| Serum uric acid levels and multiple health outcomes: umbrella review of evidence from observational studies, randomised controlled trials, and Mendelian randomisation studies | Q33770852 | ||
| Safety, tolerability, and risks associated with first- and second-generation antipsychotics: a state-of-the-art clinical review | Q33878816 | ||
| Better reporting of harms in randomized trials: an extension of the CONSORT statement | Q33983100 | ||
| Availability of large-scale evidence on specific harms from systematic reviews of randomized trials | Q35909629 | ||
| Evaluation of AMSTAR to assess the methodological quality of systematic reviews in overviews of reviews of healthcare interventions | Q36320887 | ||
| Uncertainty in heterogeneity estimates in meta-analyses | Q36987539 | ||
| AMSTAR is a reliable and valid measurement tool to assess the methodological quality of systematic reviews | Q37397185 | ||
| Integration of evidence from multiple meta-analyses: a primer on umbrella reviews, treatment networks and multiple treatments meta-analyses | Q37572176 | ||
| When Null Hypothesis Significance Testing Is Unsuitable for Research: A Reassessment | Q38616823 | ||
| Environmental risk factors and Parkinson's disease: An umbrella review of meta-analyses | Q38688811 | ||
| PRISMA harms checklist: improving harms reporting in systematic reviews | Q38718135 | ||
| Efficacy of 42 Pharmacologic Cotreatment Strategies Added to Antipsychotic Monotherapy in Schizophrenia: Systematic Overview and Quality Appraisal of the Meta-analytic Evidence. | Q38780621 | ||
| P433 | issue | 6 | |
| P921 | main subject | meta-analysis | Q815382 |
| P304 | page(s) | 537-542 | |
| P577 | publication date | 2018-07-16 | |
| P1433 | published in | Epidemiology and psychiatric sciences | Q27723686 |
| P1476 | title | The role of meta-analyses and umbrella reviews in assessing the harms of psychotropic medications: beyond qualitative synthesis | |
| P478 | volume | 27 |
| Q90435436 | Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review |
| Q92710198 | Efficacy of psychosocial interventions for mental health outcomes in low-income and middle-income countries: an umbrella review |
| Q91425768 | On the need for epidemiology in psychiatric sciences |
| Q63816232 | Safety of psychotropic medicines: looking beyond randomised evidence |
Search more.